EGFR is a member of the receptor tyrosine kinase (TK) family, widely distributed on the surface of mammalian fibroblasts, epithelial cells, and other cell types. The EGFR signaling pathway plays a crucial role in physiological processes such as cell proliferation and differentiation. When mutations occur in EGFR, it leads to the continuous activation of the EGFR signaling pathway even in the absence of ligand binding, resulting in abnormal cell proliferation. EGFR mutations have been found in various tumors, including non-small cell lung cancer, breast cancer, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC). There are several tyrosine kinase inhibitors (TKIs) targeted at EGFR mutations, such as Afatinib, Erlotinib, Gefitinib, Osimertinib (AZD 9291), and Cetuximab.BA/F3 cells are interleukin-3 (IL-3) dependent precursor B cells, and some protein kinases can substitute for IL-3 to support the growth of Ba/F3 cells. By using inhibitors to antagonize this effect, this mechanism can be utilized for the research of kinase inhibitors.
